Effects of Standard Heart Failure Therapy and Concomitant Treatment With Intravenous Furosemide or Inotropes (Dobutamine, Dopamine, and/or Milrinone) on Renal Function and Mortality in Patients Treated With Nesiritide

This publication has 9 references indexed in Scilit:

• Short-term Risk of Death After Treatment With Nesiritide for Decompensated Heart Failure
  JAMA, 2005
• Risk of Worsening Renal Function With Nesiritide in Patients With Acutely Decompensated Heart Failure
  Circulation, 2005
• Nesiritide Does Not Improve Renal Function in Patients With Chronic Heart Failure and Worsening Serum Creatinine
  Circulation, 2004
• The efficacy and safety of B-type natriuretic peptide (nesiritide) in patients with renal insufficiency and acutely decompensated congestive heart failure.
  Nephrology Dialysis Transplantation, 2004
• Relationship between heart failure treatment and development of worsening renal function among hospitalized patients11Guest Editor for this manuscript was Peter M. Okin, MD, New York Hosptial-Cornell Medical Center, New York, NY.
  American Heart Journal, 2004
• Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure
  Published by Elsevier ,2004
• National Kidney Foundation Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification
  Annals of Internal Medicine, 2003
• Effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: The PRECEDENT study
  American Heart Journal, 2002
• Effect of nesiritide versus dobutamine on short-term outcomes in the treatment of patients with acutely decompensated heart failure
  Journal of the American College of Cardiology, 2002